BioXcel Therapeutics Inc Dossier - Source-backed chat

BioXcel Therapeutics Inc

BTAINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.54

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.07Price as of 4 Sep 2026

Data confidenceNot applicable

Market Cap $2.3M

Shares Outstanding 32.8M diluted

Next Earnings Date14 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BioXcel Therapeutics is a high-risk, binary-outcome biopharmaceutical company utilizing AI for drug re-innovation. While its lead product IGALMI has a major upcoming catalyst with the FDA PDUFA date on November 14, 2026, for at-home use, the company faces severe liquidity constraints. Management has issued a going concern warning, with cash reserves of $17.2 million as of March 31, 2026, and negative working capital of $21.1 million. The company has engaged MTS Health Partners to explore strategic options, including a potential sale or merger. Given the imminent dilution or restructuring risk, a Hold recommendation is warranted until financing is secured or a strategic transaction is announced.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$14.00

High · most bullish analyst$38.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The FDA issues a Complete Response Letter (CRL) or delays approval for the at-home sNDA. Unable to raise capital under its restrictive debt covenants, the company defaults on its credit agreement, leading to severe restructuring, massive dilution, or bankruptcy.

Base CaseCentral scenario

The FDA approves IGALMI for at-home use on or around the PDUFA date of November 14, 2026. The company successfully secures dilutive financing or a co-promotion partnership to extend its cash runway, allowing a gradual commercial launch in 2027.

Bull CaseUpside scenario

Successful FDA approval of the IGALMI sNDA for at-home use in November 2026, unlocking a massive outpatient market and driving rapid commercial adoption.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA sNDA accepted for IGALMI at-home use with a clear PDUFA target date of November 14, 2026, addressing a large underserved market.
Positive clinical data from the SERENITY At-Home Phase 3 trial demonstrating consistent safety and efficacy with repeated dosing.
AI-driven drug re-innovation platform reduces early-stage development risks and timelines.

Key Investment Risks

Severe going concern risk with cash runway projected to be exhausted in mid-2026 without additional capital.
High risk of substantial shareholder dilution from emergency equity raises or debt restructuring.
Potential Nasdaq delisting if the stock price falls and remains below the $1.00 minimum threshold.

Thesis Invalidation Triggers

FDA rejection or major delay of the IGALMI at-home sNDA.
Failure to secure strategic financing or a partnership by the end of Q3 2026.
An event of default under the existing Credit Agreement covenants.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.